Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Roflumilast Foam 0.3% for Adolescent and Adult Patients with Seborrheic Dermatitis: A Randomized, Double-Blinded, Vehicle-Controlled, Phase 3 Trial.

Andrew Blauvelt,Zoe D. Draelos,Linda Stein Gold,Javier Alonso-Llamazares,Neal Bhatia,Janet DuBois,Seth B. Forman,Melinda Gooderham,Lawrence Green,Scott T. Guenthner,Adelaide A. Hebert,Edward Lain,Angela Y. Moore,Kim A. Papp,Matthew Zirwas, Saori Kato,Scott Snyder,David Krupa,Patrick Burnett,David R. Berk,David H. Chu

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2024）

Cited 0|Views27
No score
Key words
phase 3,phosphodiesterase 4 inhibitor,randomized controlled trial,roflumilast foam 0.3%,seborrheic dermatitis,STRATUM
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined